VECTUS BIOSYSTEMS LIMITED — Capital/Financing Update 2016

Feb 21, 2016

==> picture [170 x 52] intentionally omitted <==

Updated Pro Forma Statement of Financial Position Based on Actual Funds Raised

Current Assets Cash Receivables Financial Assets Total Current Assets Non-Current Assets Property, plant and equipment Total Non-Current Assets Total Assets Current Liabilities Trade and other payables Other current liabilities Provisions Financial liabilities Total Current Liabilities Non-Current Liabilities Provisions Financial liabilities Total Non-Current Liabilities Total Liabilities Net Assets Shareholders’ Equity Issued Capital Accumulates losses Total Shareholders’ Equity	Pro Forma Offer Proceeds $ 6,998,432 50,014 33,992
	7,082,438
	59,586
	59,586
	7,142,024
	172,353 119,084 163,682 20,831
	475,950 29,245 5,377
	**34,662 **
	510,572
	6,631,452
	17,289,149 (10,657,697)
	6,631,452

The above updated Consolidated Statement of Financial Position at 30 June 2015 and Pro Forma adjustments based on the actual funds received of $5,174,447 under the Share Offer and updated estimated costs associated with the Offer of $722,000. This Statement is an update on the Pro Forma Statements of Financial Position set out on page 81 of the Prospectus. Vectus Biosystems Limited (Proposed ASX Code: VBS) launched its Initial Public Offer (IPO) under a Replacement Prospectus dated 23 November 2015 that gave investors the opportunity to subscribe for up to $10,000,000 worth of new VBS ordinary fully paid shares at an issue price of $1.55 per share (the Offer). The Offer opened on 24 November 2015 and closed on 24 December 2015. The funds raised under the IPO were $5,174,447.15, being 3,338,353 ordinary shares at a price of $1.55 per share.

Dated: 22 February 2016

VECTUS BIOSYSTEMS LIMITED ABN 54 117 526 137

3-11 Primrose Avenue, Rosebery, NSW 2018 Telephone: +61 2 9662 4144 Facsimile: +61 2 9697 0933 Website: www.vectusbiosystems.com.au